Validated antibodies support stem cell purity and consistency

AMSBIO has extended its antibody portfolio to support quality assurance in stem cell research and therapeutic development. The new antibodies offer high specificity and batch-to-batch consistency for techniques including flow cytometry, immunocytochemistry, Western blotting and ELISA.

Among the latest additions are monoclonal antibodies targeting key pluripotency markers - SSEA-3 (Gb5), SSEA-4 (SialylGb5) and Lewis X (SSEA-1). These Stage-Specific Embryonic Antigens (SSEAs) are widely used to assess the undifferentiated state of human pluripotent stem cells and monitor early differentiation.

The antibodies are raised against glycan epitopes that are uniquely expressed on human stem cells, with minimal cross-reactivity to non-target glycans as confirmed by ELISA validation. This ensures accurate detection and reduces the risk of false positives in routine QC and research workflows.

Dr Philipp Boder, stem cell specialist at AMSBIO, said: “Whether for basic research or therapeutic development, antibody quality directly impacts reproducibility. Our rigorously validated antibodies help scientists confirm culture integrity and compare results across labs with confidence.” He added: “In regenerative medicine, this level of reliability is key to ensuring the safety and consistency of cell-based therapies.”

More information online